Welcome to our dedicated page for ENDP news (Ticker: ENDP), a resource for investors and traders seeking the latest updates and insights on ENDP stock.
This page contains historical news coverage for Endo International plc (ENDP), a specialty pharmaceutical company that filed for Chapter 11 bankruptcy protection. The news archive documents the company's corporate developments, product announcements, and legal challenges leading to its restructuring.
Endo operated in the specialty pharmaceuticals sector with branded products in pain management, urology, and endocrinology, alongside generic drug manufacturing through Par Pharmaceutical. News coverage spans product launches, clinical developments, regulatory decisions, earnings reports, and the substantial litigation that ultimately drove bankruptcy proceedings.
For researchers and investors studying pharmaceutical industry dynamics, this archive provides insight into how opioid-related litigation affected mid-sized specialty pharmaceutical companies. Coverage includes material announcements about settlements, restructuring efforts, and corporate strategy changes as Endo navigated its legal challenges.
Historical news for ENDP offers context for understanding specialty pharmaceutical business models, the impact of controlled substance regulations on pharmaceutical companies, and how litigation liabilities can reshape corporate trajectories. Browse past coverage to trace the company's path from operating pharmaceutical business to bankruptcy restructuring.
The Buxton Helmsley Group issued an open letter to shareholders of Endo International Plc, addressing serious issues regarding corporate malfeasance and inaccurate financial statements. BHG's letter follows private communications with the Company, highlighting concerns that may impact shareholder trust and investment stability. BHG urges a thorough review of Endo's financial practices and governance as stakeholders assess the implications for their investments in the company.
Endo International plc (NASDAQ: ENDP) reported Q1 2022 revenues of $652 million, down 9% from $718 million in Q1 2021. The company experienced a loss from continuing operations of $65 million, resulting in a diluted net loss per share of $0.28. While revenues from Sterile Injectables decreased by 22% due to generic competition, the Generic Pharmaceuticals segment saw a 3% increase, driven by the launch of the FDA-approved generic Chantix®. The company provided limited Q2 guidance amid market uncertainties, focusing on long-term product portfolio investments.
Endo International plc (NASDAQ: ENDP) has announced a new clinical study for Qwo® (collagenase clostridium histolyticum-aaes) aimed at treating moderate to severe cellulite in adult women. The study's design will be presented at the Symposium for Cosmetic Advances & Laser Education (SCALE) in Nashville, TN, from May 11-15, 2022. The multi-cohort study will explore interventions to reduce bruising associated with Qwo treatment, emphasizing Endo's commitment to ongoing research and development to enhance patient experiences. Results will be shared with healthcare providers for safety and efficacy evaluations.
Endo International plc (NASDAQ: ENDP) announced the acquisition of six injectable product candidates from Nevakar Injectables Inc. for $35 million. This acquisition significantly expands Endo's portfolio of ready-to-use injectables, aimed at improving patient care in critical settings. The first product launch is expected by 2025, with development, approval, and commercialization under Endo's control. The acquisition is anticipated to enhance operational efficiency in hospitals by reducing preparation errors and costs.
Endo International plc (NASDAQ: ENDP) announced that the Tennessee Court of Appeals has reversed a trial court's denial of a motion for recusal related to Clay County et al. v. Purdue Pharma, L.P. This ruling mandates a new judge for the ongoing case involving claims from 13 counties and 22 cities alleging Endo violated Tennessee's Drug Dealer Liability Act. Additionally, the court vacated sanctions imposed on Endo, including a default judgment for purported discovery violations, to uphold confidence in the judiciary.
Endo International plc (NASDAQ: ENDP) plans to announce its first-quarter 2022 financial results on May 5, 2022. A conference call and webcast will follow on May 6, 2022, at 7:30 am ET. The call can be accessed at a dial-in number for U.S./Canada and international callers. A replay option will be available until May 13, 2022. Endo is committed to delivering quality therapies, leveraging its global team to enhance lives.
Endo International announced the launch of premixed Ephedrine Sulfate Injection in 50 mg/10 ml single-use vials, enhancing operational efficiency for healthcare providers. This release marks the first product under an exclusive licensing agreement with Nevakar Injectables, focusing on five sterile injectables. The ready-to-use design aims to reduce waste, optimize workflow, and minimize preparation errors in hospitals, ultimately improving patient care.
Endo International (NASDAQ: ENDP) has launched its inaugural Living Our Values Award program to honor employees who exemplify the company's core values: Collaboration, Innovation, Integrity & Quality, Drive, and Empathy. Winners receive monetary awards, commemorative trophies, and recognition from the Senior Executive Leadership Team. Nominees are selected based on their contributions to the company's strategic priorities. This initiative emphasizes Endo's commitment to its mission of enhancing lives through quality therapies while celebrating employee excellence.
Endo International plc (NASDAQ: ENDP) has launched the Butt First campaign, featuring over 200 patient events to raise awareness about Qwo®, the first FDA-approved injectable treatment for cellulite in women. The campaign aims to empower women to discuss cellulite with their aesthetic providers and learn more about Qwo's benefits. With an emphasis on education and emotional connection, the campaign includes digital ads and partnerships in beauty and wellness. Notably, Qwo treats moderate to severe cellulite and has gained FDA approval since July 2020.
